OKYO Pharma Chairman Buys 10,119 Shares at $1.59, Boosts Stake to 10.5M
Panetta Partners, linked to Executive Chairman Gabriele Cerrone, acquired 10,119 OKYO Pharma shares at $1.59, lifting his stake to 10,526,416 shares. The company plans a ~150-subject Phase 2b/3 multiple-dose study of urcosimod in neuropathic corneal pain during the first half of 2026.
1. Insider Acquisition
Gabriele Cerrone, Executive Chairman through Panetta Partners Limited, purchased 10,119 OKYO Pharma ordinary shares at $1.59 each on NASDAQ, raising his total stake to 10,526,416 shares, reflecting continued confidence from the company’s leadership.
2. Urcosimod Clinical Progress
Urcosimod (OK-101) is a lipid-conjugated chemerin peptide agonist targeting ChemR23 receptors on immune and nerve cells in the eye. It demonstrated significant anti-inflammatory and pain-reducing effects in a Phase 2a trial with 18 neuropathic corneal pain subjects and in a 240-subject Phase 2 dry eye disease study.
3. Upcoming Phase 2b/3 Trial
OKYO Pharma plans to initiate a ~150-subject Phase 2b/3 multiple-dose study of urcosimod for neuropathic corneal pain in the first half of 2026, aiming to validate pain reduction findings and advance toward regulatory submission.